SHOULD ADDITIONAL VESSELS BE TREATED DURING LEFT MAIN PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM A LARGE PROSPECTIVE REGISTRY
David Power(Cardiovascular Institute of the South), Samin K. Sharma(Mount Sinai Health System), Annapoorna Kini(Mount Sinai Medical Center), Kenneth J. Smith(Mount Sinai Hospital), Parasuram Krishnamoorthy(Einstein Medical Center Philadelphia), Manish Vinayak(Icahn School of Medicine at Mount Sinai), Roxana Mehran(Mount Sinai Hospital), Pier Pasquale Leone(Montefiore Medical Center), Anastasios Roumeliotis(Cardiovascular Institute of the South), Rakhee R Makhija(Mount Sinai Hospital), Serdar Farhan(Mount Sinai Hospital), George Dangas(Mount Sinai Hospital), Anton Camaj(Columbia University Irving Medical Center), Joseph Sweeny(Mount Sinai Hospital), Johny Nicolas(Cardiovascular Institute of the South), Richard Tanner(Mount Sinai Hospital), Amit Hooda(Mount Sinai Hospital), Keisuke Yasumura(Cardiovascular Institute of the South), Samantha Sartori(Icahn School of Medicine at Mount Sinai)
Cited by 0
Related Papers
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
|New England Journal of Medicine|2016|1.5k